Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term switch study of KHK7791 in hyperphosphatemia patients on hemodialysis
jRCT2071200108Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tenapanor in hyperphosphatemia, sponsored by Kyowa Kirin. Primary endpoint: Safety of repeated KHK7791 administration over 52 weeks. Started Mar 2021; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on jRCT2071200108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200108.